A New Kind of Diabetes Drug
Both Bristol-Myers Squibb and GlaxoSmithKline are developing new drugs that block the re-absorption of excess glucose by the kidneys, allowing it to be excreted by the body instead.
The new drugs, called sodium glucose uptake transporter 2 inhibitors (SGLT-2), go by the names of dapagliflozin and sergliflozin, respectively. A few preliminary studies have shown that they led to improved glucose levels in patients.
* * *
Source: ADAClick Here To View Or Post Comments